



Contents

List of Tables	vii
List of Figures	xi
Abstract	xiii
1 Introduction	1
1.1 Dihydropyridine derivatives	1
1.2 Coumarin derivatives	4
1.3 Venlafaxine derivatives	5
1.4 About the Facility	6
1.5 References	7
2 X-ray crystallography	9
2.1 Scattering of X-rays	9
2.1.1 Thomson scattering	10
2.1.2 Compton scattering	10
2.2 Diffraction of X-rays by crystals	11
2.2.1 Diffraction pattern	12
2.2.2 Bragg's law and Ewald sphere	13
2.3 Instruments used	13
2.3.1 AFC7S single crystal diffractometer	14
2.3.2 DIPLabo image plate diffractometer	17
2.4 Data reduction	20
2.4.1 Lorentz factor	20

2.4.2	Polarisation factor	21
2.4.3	Absorption corrections	21
2.4.4	Extinction corrections	22
2.4.5	Anomalous dispersion	23
2.4.6	Thermal effects	24
2.5	Structure solution	25
2.5.1	Development of phase information	25
2.5.2	Inequalities	26
2.5.3	Equalities	27
2.5.4	Probabilities	27
2.5.5	Patterson methods	28
2.6	Structure refinement	29
2.7	Structure: constitution, configuration and conformation	31
2.7.1	Bond lengths and angles	31
2.7.2	Estimated standard deviations	31
2.7.3	Torsion angles	32
2.7.4	Ring conformations	33
2.8	References	34
3	Dihydropyridine derivatives	35
3.1	Data collection and data reduction	35
3.2	Crystal and molecular structure	36
3.3	Methyl 5-acetyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro pyridine-3-carboxylate (1)	37
3.3.1	Synthesis	37
3.3.2	Crystallisation	38
3.3.3	Crystal and molecular structure	38
3.4	2,6-dimethyl-3,5-di-N-(2'-chlorophenyl)carbamoyl-4- (4''-hydroxy phenyl)-1,4-dihydropyridine (2)	50
3.4.1	Synthesis	50
3.4.2	Crystallisation	50
3.4.3	Crystal and molecular structure	50
3.5	2,6-dimethyl-3,5-di-N-phenylcarbamoyl-4 (3'-nitro phenyl) 1,4-dihydropyridine (3)	66
3.5.1	Synthesis	66
3.5.2	Crystallisation	66
3.5.3	Crystal and molecular structure	66
3.6	3,5-dicarbethoxy-2,6-dimethyl-4-(4'-methoxy)phenyl-1, 4-dihydropyridine (4)	88
3.6.1	Synthesis	88

3.6.2	Crystallisation	88
3.6.3	Crystal and molecular structure	88
3.7	N-(3-methyl phenyl)3,5 dicarbethoxy-2,6 dimethyl-4-(4 thio methyl) phenyl-1,4-dihydropyridine (5)	101
3.7.1	Synthesis	101
3.7.2	Crystallisation	101
3.7.3	Crystal and molecular structure	101
3.8	Results	114
3.9	References	115
4	Coumarin derivatives	117
4.1	2-amino-3-ethoxycarbonyl-4-(4'-methoxy Phenyl)-4H- pyrano-[3,2-c]-chromene-6-methyl-5-one (6)	117
4.1.1	Synthesis	117
4.1.2	Crystallisation	118
4.1.3	Crystal and molecular structure	118
4.2	2-amino-3-ethoxycarbonyl-4-(4'-thiomethyl phenyl)-4H- pyrano-[3,2-c]-chromene-7,8-dimethyl-5-one (7)	132
4.2.1	Synthesis	132
4.2.2	Crystallisation	132
4.2.3	Crystal and molecular structure	132
4.3	2-amino-4(3'-chloro phenyl)-3-ethoxycarbonyl-4H-pyrano- [3,2-c]- chromene-5-one (8)	145
4.3.1	Synthesis	145
4.3.2	Crystallisation	145
4.3.3	Crystal and molecular structure	145
4.4	Results	159
4.5	References	160
5	Venlafaxine derivatives	161
5.1	1-cyano-(4-methoxyphenyl)methyl-cyclohexanol (9)	161
5.1.1	Synthesis	161
5.1.2	Crystallisation	162
5.1.3	Crystal and Molecular Structure	162
5.2	1-[2-1-(4-dimethylamino-phenyl)-ethylideneamino]-1-(4- methoxy-phenyl)-ethyl-cyclohexanol (10)	181
5.2.1	Synthesis	181
5.2.2	Crystallisation	181
5.2.3	Crystal and molecular structure	181

5.3	2-(2,6-difluorophenyl)-4a,5,6,7,8,8a-hexahydro-4a-(4-methoxyphenyl)-4H-benzo[e][1,3]oxazine (11)	195
5.3.1	Synthesis	195
5.3.2	Crystallisation	195
5.3.3	Crystal and molecular structure	195
5.4	Results	208
5.5	References	209
6	Summary	211
6.1	Dihydropyridine derivatives	211
6.2	Coumarin derivatives	216
6.3	Venlafaxine derivatives	219
6.4	References	222
A	Descriptors	223
	Colophon	225
	Publications	227
